

We are advancing a diversified portfolio of product candidates derived from our four drug classes focused on the potential treatment of cancer, infectious diseases and other serious diseases of unmet patient need:

Oncology

Drug class	Platform	Product candidate	Indication (target)	Phase 1	Phase 1/2	Phase 2	Phase 3	BioNTech rights ⁽¹⁾	Collaborator /Partner
mRNA	FixVac	BNT111	Advanced, R/R melanoma	██████████	██████████	██████████		Fully owned ⁽²⁾	
		BNT113	Metastatic / R/R HPV16+ head and neck cancer	██████████	██████████	██████████			
		BNT116	1L metastatic NSCLC	██████████	██████████	██████████			
	iNeST	BNT122 / RO7198457 (autogene cevumeran)	1L advanced melanoma	██████████	██████████	██████████		Genentech ⁽³⁾	
			Adjuvant colorectal cancer	██████████	██████████	██████████			
			Adjuvant pancreatic ductal adenocarcinoma	██████████	██████████	██████████			
		Multiple solid tumors	██████████						
	RiboMabs	BNT142	Multiple solid tumors (CD3×CLDN6)	██████████	██████████			Fully owned	
	RiboCytokines	BNT152 + BNT153	Multiple solid tumors (IL-7, IL-2)	██████████				Fully owned	
	Cell therapies	CAR T cells + CARVac	BNT211	Multiple solid tumors (CLDN6)	██████████				Fully owned
Neoantigen-based T cells		BNT221	Refractory metastatic melanoma	██████████				Fully owned	
Protein-based therapeutics	Next-generation immune checkpoint modulators	BNT311 / GEN1046 (acasinlimab)	aPD(L)1-R/R metastatic NSCLC (PD-L1×4-1BB)	██████████	██████████	██████████		Collaboration	Genmab
		BNT312 / GEN1042	Multiple solid tumors (CD40×4-1BB)	██████████	██████████	██████████			
		BNT314 / GEN1059	Multiple solid tumors (EpCAM×4-1BB)	██████████	██████████	██████████			
		BNT315 / GEN1055	Multiple solid tumors (OX40)	██████████	██████████	██████████			
		BNT322 / GEN1056	Multiple solid tumors	██████████					
		BNT316 / ONC-392 (golistobart)	aPD(L)1-R/R metastatic NSCLC (CTLA-4) Platinum-resistant ovarian cancer (CTLA-4) Metastatic castration-resistant prostate cancer (CTLA-4) Multiple solid tumors (CTLA-4)	██████████	██████████	██████████	██████████		
	Targeted cancer antibodies	BNT327 / PM8002	1L/2L+ ES-SCLC (PD-L1 x VEGF-A)	██████████	██████████	██████████		Collaboration	Biotheus
			1L/2L metastatic TNBC (PD-L1 x VEGF-A)	██████████	██████████	██████████			
		BNT327 / PM8002 + BNT325 / DB-1305	Multiple solid tumors	██████████	██████████		Collaboration	Biotheus / Duality Biologics	
		BNT321	Adjuvant pancreatic ductal adenocarcinoma (sLea) Metastatic pancreatic cancer (sLea)	██████████	██████████			Fully owned	
Antibody-drug conjugates	BNT323 / DB-1303 (trastuzumab pamirtecab)	HR+/HER2-low metastatic breast cancer (HER2)	██████████	██████████	██████████		Collaboration	Duality Biologics	
		Multiple solid tumors (HER2)	██████████	██████████					
	BNT324 / DB-1311	Multiple solid tumors (B7H3)	██████████	██████████					
	BNT325 / DB-1305	Multiple solid tumors (TROP2)	██████████	██████████					
BNT326 / YL202	Multiple solid tumors (HER3)	██████████				Collaboration	MediLink Therapeutics		
SM ⁽⁴⁾	Toll-like receptor binding	BNT411	Multiple solid tumors (TLR7)	██████████	██████████			Fully owned	

